NASDAQ · VNDA
Healthcare · Biotechnology
$5.44
Down-$0.20 (-3.58%)
Updated Aug 28, 2026, 4:16 PM
SID Score
4.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
VNDA closed at $5.44 after 21 trading sessions, up 5.02% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 27, 2026 | $5.35 | $5.48 | $5.27 | $5.44 | 545.58K |
| Aug 26, 2026 | $5.43 | $5.43 | $5.24 | $5.35 | 928.37K |
| Aug 25, 2026 | $5.34 | $5.4999 | $5.34 | $5.44 | 876.37K |
| Aug 24, 2026 | $5.335 | $5.37 | $5.20 | $5.33 | 774.3K |
| Aug 21, 2026 | $5.42 | $5.42 | $5.265 | $5.28 | 656.79K |
| Aug 20, 2026 | $5.52 | $5.52 | $5.315 | $5.38 | 915.77K |
| Aug 19, 2026 | $5.50 | $5.59 | $5.39 | $5.57 | 898.03K |
| Aug 18, 2026 | $5.23 | $5.48 | $5.23 | $5.44 | 996.31K |
| Aug 17, 2026 | $5.15 | $5.335 | $5.13 | $5.26 | 795.41K |
| Aug 14, 2026 | $5.04 | $5.28 | $4.955 | $5.22 | 965.07K |
| Aug 13, 2026 | $5.20 | $5.24 | $4.995 | $5.03 | 864.99K |
| Aug 12, 2026 | $4.95 | $5.26 | $4.92 | $5.19 | 1.08M |
| Aug 11, 2026 | $5.05 | $5.09 | $4.849 | $4.93 | 1.07M |
| Aug 10, 2026 | $4.93 | $5.065 | $4.80 | $5.02 | 2M |
| Aug 7, 2026 | $5.16 | $5.17 | $4.97 | $5.00 | 1.31M |
| Aug 6, 2026 | $4.64 | $5.20 | $4.4475 | $5.115 | 2.34M |
| Aug 5, 2026 | $5.33 | $5.41 | $5.04 | $5.09 | 1.6M |
| Aug 4, 2026 | $5.24 | $5.39 | $5.20 | $5.33 | 727.5K |
| Aug 3, 2026 | $5.10 | $5.26 | $5.02 | $5.23 | 719.84K |
| Jul 31, 2026 | $5.16 | $5.16 | $4.95 | $5.10 | 540.61K |
| Jul 30, 2026 | $5.08 | $5.195 | $5.03 | $5.18 | 990.08K |
The latest Smart Investors Daily articles mentioning VNDA.
VNDA research
Company profile and research snapshot.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 10, 2026 | B. Riley Securities | Buy | — |
| Aug 10, 2026 | HC Wainwright & Co. | Buy | — |
| May 11, 2026 | HC Wainwright & Co. | Buy | — |
| Mar 5, 2026 | Truist Securities | Buy | — |
| Feb 23, 2026 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 24, 2026
The US Food and Drug Administration (FDA) and Japan's Ministry of Health, Labour and Welfare have previously granted Orphan Drug Designation to imsidolimab for the treatment of GPP.This marks the first time the
Yahoo · Aug 12, 2026
Fanapt surges 23% as Vanda expands psychiatry franchise amid pipeline progress.
Benzinga · Aug 10, 2026
B. Riley Securities analyst Madison El-Saadi reiterates Vanda Pharmaceuticals (NASDAQ:VNDA) with a Buy and lowers the price target from $17 to $12.
Benzinga · Aug 10, 2026
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Vanda Pharmaceuticals (NASDAQ:VNDA) with a Buy and lowers the price target from $21 to $20.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning VNDA.
